Pirfenidone (AP01)
Small molecule
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Company guidance: topline data expected second half of 2027 (Avalyn Pharma Inc., 12 Aug 2026). “Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027” Source ↗
Company guidance: data expected second half of 2027 (Avalyn Pharma Inc., 12 Nov 2026). “Results from the MIST study of AP01, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF) are anticipated in the second half of 2027.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06329401 NCT06329401 · Progressive Pulmonary Fibrosis (non-IPF ILD) Registry: NCT06329401 | 2 | To evaluate the effect of AP01 high dose twice a day (BID) or AP01 low dose twice a day (BID) compared to placebo twice a day (BID) (Week 52) 2027-06 | In progress: results expected 1 Jun 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Pirfenidone (AP01) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.